Pfizer Corporation

Amgen Fremont Inc.

Bristol-Myers Squibb Compnay

Agouron Pharmaceuticals, Inc.

Dana Dan Hu-Lowe

Michael Aidan North

Xin Jiang

Jianying Wang

James A Thomson

Vahe Bedian

Steven Lee Bender

Shannon Marie Karlicek

Grant Raymond Wickman

Jingchuan Zhang

Karin Kristina Amundson

Haichun Huang

Brigitte Devaux

Peter Brams

Haibin Chen

Kristopher Toy

Mark Yamanaka

Dawn M Tanamachi

Lan Yang

Sirid-Aimee Kellermann

Gerald Fries Casperson

Gang Li

Tim Sproul

Shelley Sims Belouski

Grant Wickman

Sirid Aimee Kellerman

Sirid-Aimée Kellerman

David Ray Shalinsky

Shelly Sims Belouski

Tim W Sproul

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

Human monoclonal antibodies to activin receptor-like kinase-1

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin &#x3b1;5&#x3b2;1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-&#x3b1;5&#x3b2;1 antibodies or antigen binding portions thereof described herein.

Alpha5-beta1 antibodies and their uses

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

Alpha 5-beta 1 antibodies and their uses

Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Growing community of inventors

Encinitas, CA, United States of America

Dana Dan Hu-Lowe